Only those with a vast knowledge of the pharma business and deep, deep pockets can guess whether or not this company is a good "buy-out" bet.

For us late comers a buyout premium would likely recoup most of our investment dollars and breaking even is always the second best event (making money of course is the preferred alternative).

For those who are "long in the tooth" with respect to this venture, any buy-out at this juncture would likely just solidify losses and not be received with open arms.

For me, it is "ride it out" time. My position is at a level I consider full so I am not adding nor subtracting for the moment.

Onward and Upward.